Navigation Links
WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering
Date:1/20/2012

LOS ANGELES, Jan. 20, 2012 /PRNewswire/ -- WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012.  A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000.  Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer.  WestPark Capital, Inc. acted as placement agent for the offering.

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.  The offering was made only by Confidential Private Placement Memorandum.  Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide.  WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services.  Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com. Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a new generation of diagnostic and therapeutic drugs based on a new family of nano-biopolymers.  Arrogene was founded in 2007 to commercialize a new cancer targeting technology and a proprietary molecular delivery platform that interferes with cancer targets to inhibit and finally eradicate tumor progression.  Additional information about Arrogene is available at www.arrogene.com.

Contact:
WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

 


'/>"/>
SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
3. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/3/2017)... 2017  Opioid addiction and other drugs of abuse, ... and threatening outcomes, were problems taken on directly as ... that support them, met this week. This according to ... drugs of abuse, procalcitonin and acute kidney injury were ... 69th meeting in San Diego, CA. ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Nightingale College continues the semiannual Give Back Day ... time Nightingale College dedicates to serving and volunteering for organizations that provide indispensable resources ... or those that need a little extra help. , The College’s Give Back ...
(Date:8/23/2017)... ... 23, 2017 , ... Cirrus Medical Staffing, one of the ... http://www.cirrusmedicalstaffing.com . The new site pairs a robust job search with a visually ... traveling on short-term assignments to healthcare facilities around the country. , “We built ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... has returned home to Indiana, and is now seeing patients at Boling Vision ... that specializes in the diagnosis and treatment of eye disease, medical retina, high-technology ...
(Date:8/23/2017)... ... August 23, 2017 , ... Silicon Valley Hair Institute, a ... blog archive organized month-by-month. The new rotation of archived blog posts can provide a ... searching information about hair transplantation can review details online and then reach out for ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage ... - for Risk Management Solution Innovations and Security Solution for Government Innovations. Both ... in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , The ...
Breaking Medicine News(10 mins):